Main
glioma, tumors, tumor
PROLIFERATION, GLIOMA, TUMORS, TUMOR
Pediatric low-grade glioma (pLGG) is the most common childhood central nervous system (CNS) tumor, representing approximately 30% of pediatric brain tumorsMost pLGGs are driven by genomic alterations affecting components of the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway, which regulates cell proliferation and survivalA randomized phase 2 trial, which investigated the type I RAF inhibitor dabrafenib plus the MEK inhibitor trametinib versus vincristine and carboplatin as first-line therapy in patients with pLGG with a BRAF V600 mutation, showed the superiority of dabrafenib plus trametinib over vincristine–carboplatin in this settingTovorafenib (previously known as DAY101, TAK-580, MLN2480 or BIIB024) is an investigational, oral, selective, CNS-penetrant type II RAF inhibitor in clinical development for the treatment of patients with tumors harboring an activating The phase 2 FIREFLY-1 (PNOC026; 